SEC Form 4 · accession 0001209191-15-033248
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Margaret G McGlynn
Director
Period of report
Apr 6, 2015
Accepted (ET)
Apr 8, 2015 · 7:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 6, 2015 | M | 12,500 | $53.85 | A | 13,588 | D | |
| Common StockF2,F3 | Apr 6, 2015 | S | 2,200 | $117.14 | D | 11,388 | D | |
| Common StockF3,F4 | Apr 6, 2015 | S | 6,000 | $118.32 | D | 5,388 | D | |
| Common StockF3,F5 | Apr 6, 2015 | S | 3,900 | $118.97 | D | 1,488 | D | |
| Common StockF3,F6 | Apr 6, 2015 | S | 400 | $119.78 | D | 1,088 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF7 | $53.85 | Apr 6, 2015 | A | 12,500 | A | — | May 31, 2021 | Common Stock | 12,500 | 7,500 | D |
Explanation of responses
- F1Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $117.14 (range $116.56 to $117.53).
- F3Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $118.32 (range $117.64 to $118.63).
- F5Open market sales reported on this line occurred at a weighted average price of $118.97 (range $118.64 to $119.58).
- F6Open market sales reported on this line occurred at a weighted average price of $119.78 (range $119.72 to $119.95).
- F7Fully vested.